Indication: This product is suitable for moderate and severe infections caused by Streptococcus, Staphylococcus and anaerobic bacteria (including Bacteroides fragilis, Clostridium perfringens, Actinomycetes, etc.), such as aspiration pneumonia, empyema, lung abscess, osteomyelitis, abdominal infection, pelvic infection and sepsis.

Indication: The following infections caused by bacteria sensitive to this drug from the genera Staphylococcus aureus, Streptococcus (except enterococci), anaerobic cocci, anaerobic streptococci, Escherichia coli, Citrobacter, Klebsiella, Enterobacter, Proteus, Proteus morganii, Pseudomonas, Haemophilus influenzae, Acinetobacter, and Bacteroides: 1. Sepsis; 2. Secondary infections of burns, surgical incisions, etc.; 3. Pharyngitis (throat abscess), acute bronchitis , tonsillitis (peritonsillitis, peritonsillar abscess), chronic bronchitis, bronchiectasis (when infected), secondary infection of chronic respiratory diseases, pneumonia, lung abscess, empyema; 4. pyelitis, cholangitis; 5. peritonitis (including pelvic peritonitis, bladder and rectal pouch abscess); 6. adnexitis, intrauterine infection, pelvic inflammatory disease, parametrial connective tissue inflammation, vestibular glanditis; 7. meningitis; 8. jaw arthritis, cellulitis around the jaw.

Indication: The following infections caused by bacteria sensitive to this drug from the genera Staphylococcus aureus, Streptococcus (except enterococci), anaerobic cocci, anaerobic streptococci, Escherichia coli, Citrobacter, Klebsiella, Enterobacter, Proteus, Proteus morganii, Pseudomonas, Haemophilus influenzae, Acinetobacter, and Bacteroides: 1. Sepsis; 2. Secondary infections of burns, surgical incisions, etc.; 3. Pharyngitis (throat abscess), acute bronchitis , tonsillitis (peritonsillitis, peritonsillar abscess), chronic bronchitis, bronchiectasis (when infected), secondary infection of chronic respiratory diseases, pneumonia, lung abscess, empyema; 4. pyelitis, cholangitis; 5. peritonitis (including pelvic peritonitis, bladder and rectal pouch abscess); 6. adnexitis, intrauterine infection, pelvic inflammatory disease, parametrial connective tissue inflammation, vestibular glanditis; 7. meningitis; 8. jaw arthritis, cellulitis around the jaw.

Indication: This product is suitable for the following infectious diseases caused by Gram-positive bacteria: 1. Tonsillitis, suppurative otitis media, sinusitis, etc. 2. Acute bronchitis, acute exacerbation of chronic bronchitis, pneumonia, lung abscess and bronchiectasis combined infection, etc. 3. Skin and soft tissue infections: furuncle, carbuncle, abscess, cellulitis, trauma and surgical infection, etc. 4. Urinary system infection: acute urethritis, acute pyelonephritis, prostatitis, etc. 5. Others: osteomyelitis, sepsis, peritonitis and oral infection, etc. This product is suitable for various infectious diseases caused by anaerobic bacteria: 1. Empyema, lung abscess, anaerobic lung disease. 2. Skin and soft tissue infection, sepsis. 3. Intra-abdominal infection: peritonitis, intra-abdominal abscess. 4. Female pelvic and genital infections: endometritis, non-gonococcal fallopian tube and ovarian abscess, pelvic cellulitis and post-gynecological surgery infection, etc.

Indication: This product is suitable for the following infectious diseases caused by Gram-positive bacteria: 1. Tonsillitis, suppurative otitis media, sinusitis, etc. 2. Acute bronchitis, acute exacerbation of chronic bronchitis, pneumonia, lung abscess and bronchiectasis combined infection, etc. 3. Skin and soft tissue infections: furuncle, carbuncle, abscess, cellulitis, trauma and surgical infection, etc. 4. Urinary system infection: acute urethritis, acute pyelonephritis, prostatitis, etc. 5. Others: osteomyelitis, sepsis, peritonitis and oral infection, etc. This product is suitable for various infectious diseases caused by anaerobic bacteria: 1. Empyema, lung abscess, anaerobic lung disease. 2. Skin and soft tissue infection, sepsis. 3. Intra-abdominal infection: peritonitis, intra-abdominal abscess. 4. Female pelvic and genital infections: endometritis, non-gonococcal fallopian tube and ovarian abscess, pelvic cellulitis and post-gynecological surgery infection, etc.

Indication: This product is suitable for the treatment of the following infections caused by Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Proteus, Morganella morganii, Providencia, Peptostreptococcus, Bacteroides, Prevotella (except Prevotella biloba) that are sensitive to cefmetazole sodium: 1. Sepsis 2. Acute bronchitis, pneumonia, lung abscess, empyema, secondary infection of chronic respiratory diseases 3. Cystitis, pyelonephritis 4. Peritonitis 5. Cholecystitis, cholangitis 6. Bartholinitis, intrauterine infection, adnexitis, parametritis 7. Cellulitis around the jaws, jaw inflammation In the clinical studies (including double-blind trials) of 2,819 cases of intravenous injection, intravenous drip and intramuscular injection in 137 hospitals in Japan, the clinical results of 1,409 cases that can be judged as effective and belong to the approved indications of this product are as follows (for refractory or severe infections, the daily dose is increased to 4 grams (potency) for adults and 150 mg (potency) for children according to symptoms)/kg body weight): 1. Sepsis: The total effective rate for sepsis caused by Staphylococcus aureus, Escherichia coli and Klebsiella pneumoniae is 80.6% (25/31), and the dosage is 2-4g per day for adults and 50-150mg/kg for children. 2. Respiratory system infection: The total effective rate for respiratory tract infection caused by Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Proteus, Morganella morganii, Providencia, etc. is 79.7% (267/335). The dosage for drip or intravenous injection is 2-4g per day. In the double-blind trial, the efficacy of this product has been verified. 3. Biliary tract infection: This product is well excreted into bile and can reach a high concentration in bile. The total effective rate for cholecystitis and cholangitis caused by Escherichia coli and Klebsiella pneumoniae is 83.1% (49/59). The dosage is 2~4g per day. 4. Peritonitis: The total effective rate for peritonitis caused by Escherichia coli, Klebsiella pneumoniae, Bacteroides, Prevotella (except Prevotella biloba), etc. is 87.596 (161/184). Most of them are intravenous drips, and the dosage is 2~4g per day. 5. Urinary tract infection: The total effective rate for cystitis and pyelonephritis caused by Escherichia coli, Klebsiella pneumoniae, Proteus, Morganella kurschniki, Providencia, etc. is 73.1% (302/413). The dosage is mostly 1~2g per day. The results of a double-blind controlled trial on chronic complicated urinary tract infections have proved the efficacy of this product. 6. Gynecology and Obstetrics: The total effective rate for vestibular glanditis, intrauterine infection, adnexitis, and parametrial tissue inflammation caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Peptostreptococcus, Bacteroides, and Prevotella (except Prevotella biloba) is 94.796 (232/245). The dosage is usually 2-4g per day. 7. Oral Surgery: The total effective rate for perimandibular cellulitis and jaw inflammation caused by Peptostreptococcus is 83.896 (119/142). The dosage is usually 2-4g per day.

Indication: This product is suitable for the treatment of the following infections caused by Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Proteus, Morganella morganii, Providencia, Peptostreptococcus, Bacteroides, Prevotella (except Prevotella biloba) that are sensitive to cefmetazole sodium: 1. Sepsis 2. Acute bronchitis, pneumonia, lung abscess, empyema, secondary infection of chronic respiratory diseases 3. Cystitis, pyelonephritis 4. Peritonitis 5. Cholecystitis, cholangitis 6. Bartholinitis, intrauterine infection, adnexitis, parametritis 7. Cellulitis around the jaws, jaw inflammation In the clinical studies (including double-blind trials) of 2,819 cases of intravenous injection, intravenous drip and intramuscular injection in 137 hospitals in Japan, the clinical results of 1,409 cases that can be judged as effective and belong to the approved indications of this product are as follows (for refractory or severe infections, the daily dose is increased to 4 grams (potency) for adults and 150 mg (potency) for children according to symptoms)/kg body weight): 1. Sepsis: The total effective rate for sepsis caused by Staphylococcus aureus, Escherichia coli and Klebsiella pneumoniae is 80.6% (25/31), and the dosage is 2-4g per day for adults and 50-150mg/kg for children. 2. Respiratory system infection: The total effective rate for respiratory tract infection caused by Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Proteus, Morganella morganii, Providencia, etc. is 79.7% (267/335). The dosage for drip or intravenous injection is 2-4g per day. In the double-blind trial, the efficacy of this product has been verified. 3. Biliary tract infection: This product is well excreted into bile and can reach a high concentration in bile. The total effective rate for cholecystitis and cholangitis caused by Escherichia coli and Klebsiella pneumoniae is 83.1% (49/59). The dosage is 2~4g per day. 4. Peritonitis: The total effective rate for peritonitis caused by Escherichia coli, Klebsiella pneumoniae, Bacteroides, Prevotella (except Prevotella biloba), etc. is 87.596 (161/184). Most of them are intravenous drips, and the dosage is 2~4g per day. 5. Urinary tract infection: The total effective rate for cystitis and pyelonephritis caused by Escherichia coli, Klebsiella pneumoniae, Proteus, Morganella kurschniki, Providencia, etc. is 73.1% (302/413). The dosage is mostly 1~2g per day. The results of a double-blind controlled trial on chronic complicated urinary tract infections have proved the efficacy of this product. 6. Gynecology and Obstetrics: The total effective rate for vestibular glanditis, intrauterine infection, adnexitis, and parametrial tissue inflammation caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Peptostreptococcus, Bacteroides, and Prevotella (except Prevotella biloba) is 94.796 (232/245). The dosage is usually 2-4g per day. 7. Oral Surgery: The total effective rate for perimandibular cellulitis and jaw inflammation caused by Peptostreptococcus is 83.896 (119/142). The dosage is usually 2-4g per day.

Indication: This product is suitable for the treatment of the following infections caused by Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Proteus, Morganella morganii, Providencia, Peptostreptococcus, Bacteroides, Prevotella (except Prevotella biloba) that are sensitive to cefmetazole sodium: 1. Sepsis 2. Acute bronchitis, pneumonia, lung abscess, empyema, secondary infection of chronic respiratory diseases 3. Cystitis, pyelonephritis 4. Peritonitis 5. Cholecystitis, cholangitis 6. Bartholinitis, intrauterine infection, adnexitis, parametritis 7. Cellulitis around the jaws, jaw inflammation In the clinical studies (including double-blind trials) of 2,819 cases of intravenous injection, intravenous drip and intramuscular injection in 137 hospitals in Japan, the clinical results of 1,409 cases that can be judged as effective and belong to the approved indications of this product are as follows (for refractory or severe infections, the daily dose is increased to 4 grams (potency) for adults and 150 mg (potency) for children according to symptoms)/kg body weight): 1. Sepsis: The total effective rate for sepsis caused by Staphylococcus aureus, Escherichia coli and Klebsiella pneumoniae is 80.6% (25/31), and the dosage is 2-4g per day for adults and 50-150mg/kg for children. 2. Respiratory system infection: The total effective rate for respiratory tract infection caused by Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Proteus, Morganella morganii, Providencia, etc. is 79.7% (267/335). The dosage for drip or intravenous injection is 2-4g per day. In the double-blind trial, the efficacy of this product has been verified. 3. Biliary tract infection: This product is well excreted into bile and can reach a high concentration in bile. The total effective rate for cholecystitis and cholangitis caused by Escherichia coli and Klebsiella pneumoniae is 83.1% (49/59). The dosage is 2~4g per day. 4. Peritonitis: The total effective rate for peritonitis caused by Escherichia coli, Klebsiella pneumoniae, Bacteroides, Prevotella (except Prevotella biloba), etc. is 87.596 (161/184). Most of them are intravenous drips, and the dosage is 2~4g per day. 5. Urinary tract infection: The total effective rate for cystitis and pyelonephritis caused by Escherichia coli, Klebsiella pneumoniae, Proteus, Morganella kurschniki, Providencia, etc. is 73.1% (302/413). The dosage is mostly 1~2g per day. The results of a double-blind controlled trial on chronic complicated urinary tract infections have proved the efficacy of this product. 6. Gynecology and Obstetrics: The total effective rate for vestibular glanditis, intrauterine infection, adnexitis, and parametrial tissue inflammation caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Peptostreptococcus, Bacteroides, and Prevotella (except Prevotella biloba) is 94.796 (232/245). The dosage is usually 2-4g per day. 7. Oral Surgery: The total effective rate for perimandibular cellulitis and jaw inflammation caused by Peptostreptococcus is 83.896 (119/142). The dosage is usually 2-4g per day.

Indication: This product is suitable for the treatment of the following infections caused by Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Proteus, Morganella morganii, Providencia, Peptostreptococcus, Bacteroides, Prevotella (except Prevotella biloba) that are sensitive to cefmetazole sodium: 1. Sepsis 2. Acute bronchitis, pneumonia, lung abscess, empyema, secondary infection of chronic respiratory diseases 3. Cystitis, pyelonephritis 4. Peritonitis 5. Cholecystitis, cholangitis 6. Bartholinitis, intrauterine infection, adnexitis, parametritis 7. Cellulitis around the jaws, jaw inflammation In the clinical studies (including double-blind trials) of 2,819 cases of intravenous injection, intravenous drip and intramuscular injection in 137 hospitals in Japan, the clinical results of 1,409 cases that can be judged as effective and belong to the approved indications of this product are as follows (for refractory or severe infections, the daily dose is increased to 4 grams (potency) for adults and 150 mg (potency) for children according to symptoms)/kg body weight): 1. Sepsis: The total effective rate for sepsis caused by Staphylococcus aureus, Escherichia coli and Klebsiella pneumoniae is 80.6% (25/31), and the dosage is 2-4g per day for adults and 50-150mg/kg for children. 2. Respiratory system infection: The total effective rate for respiratory tract infection caused by Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Proteus, Morganella morganii, Providencia, etc. is 79.7% (267/335). The dosage for drip or intravenous injection is 2-4g per day. In the double-blind trial, the efficacy of this product has been verified. 3. Biliary tract infection: This product is well excreted into bile and can reach a high concentration in bile. The total effective rate for cholecystitis and cholangitis caused by Escherichia coli and Klebsiella pneumoniae is 83.1% (49/59). The dosage is 2~4g per day. 4. Peritonitis: The total effective rate for peritonitis caused by Escherichia coli, Klebsiella pneumoniae, Bacteroides, Prevotella (except Prevotella biloba), etc. is 87.596 (161/184). Most of them are intravenous drips, and the dosage is 2~4g per day. 5. Urinary tract infection: The total effective rate for cystitis and pyelonephritis caused by Escherichia coli, Klebsiella pneumoniae, Proteus, Morganella kurschniki, Providencia, etc. is 73.1% (302/413). The dosage is mostly 1~2g per day. The results of a double-blind controlled trial on chronic complicated urinary tract infections have proved the efficacy of this product. 6. Gynecology and Obstetrics: The total effective rate for vestibular glanditis, intrauterine infection, adnexitis, and parametrial tissue inflammation caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Peptostreptococcus, Bacteroides, and Prevotella (except Prevotella biloba) is 94.796 (232/245). The dosage is usually 2-4g per day. 7. Oral Surgery: The total effective rate for perimandibular cellulitis and jaw inflammation caused by Peptostreptococcus is 83.896 (119/142). The dosage is usually 2-4g per day.

Indication: The following infections caused by bacteria sensitive to this product among Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Proteus (indole-positive and -negative), Bacteroides, Peptococcus and Peptostreptococcus: septicemia; bronchitis, bronchiectasis infection, pneumonia, secondary infection of chronic respiratory diseases, pulmonary suppuration (lung abscess), empyema; cholangitis, cholecystitis; peritonitis; pyelonephritis, cystitis; Bartholinitis, intrauterine infection, adnexitis, parametritis; cellulitis around the jaws, jaw inflammation.